INGN

In the past six months, Inogen's stock declined by 40.65% from $8.66 on September 22, 2025, to $5.14 on September 18, 2026, trading at $6.18 as of October 9, 2026. Key events include a 3.4% increase in Q1 2026 revenue to $85.1 million, driven by international portable oxygen concentrator demand, despite a widened GAAP net loss. Q2 2026 revenue grew 3.0% year-over-year to $95.1 million, leading to a raised full-year adjusted EBITDA guidance to approximately $4.0 million, a 48.1% increase from 2025, with international sales growing while U.S. sales and rentals declined. The company announced an agreement to sell its U.S. oxygen rental business to Rotech Healthcare for up to $24.8 million, expected to close in Q4 2026 and be accretive to growth and adjusted operating income. Contingent on this sale, the board increased its share repurchase authorization from $30.0 million to $45.0 million, extending it through June 30, 2028. On October 10, 2026, Inogen shares broke above their 50-day moving average, reaching $6.28 and trading at $6.18, up 4.0%. Analyst sentiment is mixed, with Weiss Ratings giving a "sell (D-)" and MarketBeat's overall consensus being a "Moderate Buy".